诺诚健华(09969)今日盘中股价大幅拉升，涨幅达到5.11%，引起市场关注。
消息面上，公司此前发布了2026年第一季度业绩报告，业绩表现极为亮眼。报告显示，公司第一季度实现营业收入5.29亿元，同比增长38.65%；归属于上市公司股东的净利润达到1.06亿元，同比大幅增长488.93%。业绩暴增主要得益于核心产品奥布替尼持续放量、新药坦昔妥单抗和佐来曲替尼开始贡献收入，以及公司与Zenas BioPharma的授权许可协议完成后续里程碑交付。
这份远超市场预期的一季报显著增强了投资者对公司未来增长潜力的信心，推动资金在交易时段内积极买入，从而带动股价强势上涨。公司表示，其商业化体系已趋于成熟，研发管线推进顺利，未来将保持高质量增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.